Tag #Eli Lilly

Showing 13 to 24 of 27 results

theglobeandmail.com

🌐 85% Global Worthiness

May 1, 16:13

Eli Lilly Q1 Earnings Beat Expectations Despite Zepbound Reimbursement Setback

Eli Lilly exceeded Q1 2024 earnings expectations with \$12.73 billion in revenue and \$3.34 adjusted EPS, but CVS's removal of Zepbound from its formulary, starting July 1, caused a 5 percent stock drop due to price competition with Novo Nordisk's Wegovy; Lilly holds a 53.3 percent U.S. market share...

Eli Lilly Q1 Earnings Beat Expectations Despite Zepbound Reimbursement Setback

Eli Lilly exceeded Q1 2024 earnings expectations with \$12.73 billion in revenue and \$3.34 adjusted EPS, but CVS's removal of Zepbound from its formulary, starting July 1, caused a 5 percent stock drop due to price competition with Novo Nordisk's Wegovy; Lilly holds a 53.3 percent U.S. market share...

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the primary impact of CVS Health's decision to remove Eli Lilly's Zepbound from its reimbursement list?

Eli Lilly's Q1 2024 earnings surpassed expectations, reaching \$12.73 billion in revenue and \$3.34 in adjusted earnings per share. However, CVS Health's decision to remove Zepbound from its reimbursement list, effective July 1, caused a 5 percent drop in Lilly's stock price. This decision follows price negotiations between CVS and Novo Nordisk for Wegovy.

bbc.com

🌐 85% Global Worthiness

Apr 4, 04:10

Trump Tariffs: Pharmaceutical CEO Warns of Economic Consequences

Eli Lilly CEO David Ricks states that President Trump's tariffs are a watershed moment in US economic history, impacting pharmaceutical investment and potentially reducing research and development; the UK's life sciences sector is also in decline due to slow regulation and poor uptake of new medicin...

Trump Tariffs: Pharmaceutical CEO Warns of Economic Consequences

Eli Lilly CEO David Ricks states that President Trump's tariffs are a watershed moment in US economic history, impacting pharmaceutical investment and potentially reducing research and development; the UK's life sciences sector is also in decline due to slow regulation and poor uptake of new medicin...

Progress

44% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How do the tariffs affect Eli Lilly's global strategy and investment decisions, and what adjustments are they making?

Ricks's comments highlight the interconnectedness of global supply chains and the potential consequences of protectionist policies. The tariffs, while intending to boost US manufacturing, risk harming innovation and investment in crucial sectors like pharmaceuticals. Eli Lilly's continued investment in Ireland despite the tariffs underscores the limitations of protectionism and the ongoing importance of global markets.

repubblica.it

🌐 85% Global Worthiness

Feb 25, 13:12

Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market

Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.

Eli Lilly's Oral Semaglutide Shows Promise, Poised to Disrupt Weight-Loss Market

Eli Lilly's oral semaglutide, orforglipron, shows promising results with 14.7% average weight loss in phase two trials, prompting a $550 million revenue projection and expected launch next year, intensifying competition in the $25 billion global obesity drug market.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the significance of Eli Lilly's oral semaglutide, orforglipron, in the context of the global obesity treatment market?

Eli Lilly's oral semaglutide, orforglipron, aims to revolutionize weight loss treatment, potentially surpassing the revenue generated by injectable semaglutide. Phase two trials showed an average weight loss of 14.7% over nine months, with side effects comparable to the injectable version. Final phase three results are expected in April, with a projected launch next year.",

theglobeandmail.com

🌐 75% Global Worthiness

Feb 6, 19:08

Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments

Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.

Eli Lilly Exceeds Profit Forecasts Despite Sales Disappointments

Eli Lilly, exceeding analysts' expectations, forecasts higher-than-expected annual profit despite recent sales misses for its Mounjaro and Zepbound drugs; the company's stock rose 1 percent in premarket trading.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What are the key risks and uncertainties that could affect Eli Lilly's ability to achieve its ambitious sales targets for 2025?

Eli Lilly's focus on expanding Mounjaro into new markets, coupled with its marketing strategy for Zepbound, suggests a proactive approach to market share competition with Novo Nordisk. The success of these strategies will be crucial in determining Lilly's ability to maintain its leading position in the growing weight-loss market.

cnbc.com

🌐 75% Global Worthiness

Jan 21, 16:12

Cramer's Trust Adjusts Portfolio: Sells Coterra, Honeywell; Buys Eli Lilly

Jim Cramer's Charitable Trust will sell 200 shares of Coterra Energy, 45 shares of Honeywell, and buy 10 shares of Eli Lilly on Tuesday, adjusting its portfolio weighting based on profit-taking, fundamental concerns, and long-term growth prospects.

Cramer's Trust Adjusts Portfolio: Sells Coterra, Honeywell; Buys Eli Lilly

Jim Cramer's Charitable Trust will sell 200 shares of Coterra Energy, 45 shares of Honeywell, and buy 10 shares of Eli Lilly on Tuesday, adjusting its portfolio weighting based on profit-taking, fundamental concerns, and long-term growth prospects.

Progress

36% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

What immediate market impacts will result from Jim Cramer's Charitable Trust's portfolio adjustments?

On Tuesday, Jim Cramer's Charitable Trust will adjust its portfolio by selling 200 shares of Coterra Energy (CTRA) at $29.31, 45 shares of Honeywell (HON) at $224.26, and buying 10 shares of Eli Lilly (LLY) at $727.50. These trades will slightly alter the weighting of these stocks in the portfolio.

forbes.com

🌐 85% Global Worthiness

Jan 1, 22:06

Zepbound Poised to Exacerbate Healthcare Cost Increases

Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...

Zepbound Poised to Exacerbate Healthcare Cost Increases

Eli Lilly's new anti-obesity drug, Zepbound, is projected to become a major cost driver for health insurers in 2025 due to its superior efficacy compared to existing GLP-1 drugs like Wegovy, adding to the already 1% increase in employer health costs caused by these drugs and raising premiums by 9% t...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the projected impact of Zepbound on healthcare costs for insurers and government programs, considering its efficacy compared to existing GLP-1 drugs?

Zepbound", a new anti-obesity drug from Eli Lilly, is projected to significantly increase healthcare costs for insurers and government programs in 2025. Its superior efficacy, demonstrated in the SURMOUNT-5 trial showing 20.2% average weight loss versus Wegovy's 13.7%, positions it to surpass existing GLP-1 drugs as the leading cost driver. This follows a trend where GLP-1 drugs already increased employer health costs by 1% in 2025.

cincodias.elpais.com

🌐 85% Global Worthiness

Apr 22, 10:15

Eli Lilly's Weight-Loss Pill Poised for Market Disruption

Eli Lilly's new weight-loss pill, showing 8% weight loss in trials, offers a more accessible treatment option compared to injectables, potentially reaching a larger patient base and generating \$100 billion in sales by 2030.

Eli Lilly's Weight-Loss Pill Poised for Market Disruption

Eli Lilly's new weight-loss pill, showing 8% weight loss in trials, offers a more accessible treatment option compared to injectables, potentially reaching a larger patient base and generating \$100 billion in sales by 2030.

Progress

64% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the key advantage of Eli Lilly's new weight-loss pill compared to existing injectable treatments, and what are its projected market implications?

Eli Lilly's new weight-loss pill, currently in trials, shows patients losing almost 8% of their weight with the highest dose (36mg daily) and statistically significant blood sugar reduction over 40 weeks. While less effective than Lilly's injectable, Mounjaro, the pill format offers increased patient compliance due to ease of use and reduced side effects.

forbes.com

🌐 85% Global Worthiness

Mar 3, 07:09

Eli Lilly's $27 Billion Investment: High-Risk, High-Reward Strategy

Eli Lilly will invest $27 billion in four new US manufacturing plants over five years, creating thousands of jobs, a strategic move amid potential import tariffs; despite its high valuation (P/E 120.8, P/S 17.8 vs S&P 500's 24.4 and 3.1), the company shows strong revenue growth (27.4% last 12 months...

Eli Lilly's $27 Billion Investment: High-Risk, High-Reward Strategy

Eli Lilly will invest $27 billion in four new US manufacturing plants over five years, creating thousands of jobs, a strategic move amid potential import tariffs; despite its high valuation (P/E 120.8, P/S 17.8 vs S&P 500's 24.4 and 3.1), the company shows strong revenue growth (27.4% last 12 months...

Progress

52% Bias Score

ShareSaveArticle

Decent Work and Economic Growth

12345678

Previous 1 of 8 Next

How does Eli Lilly's growth and profitability compare to the S&P 500, and what are the implications of its high valuation ratios?

The investment counters potential import tariffs, showcasing proactive risk management. High revenue growth (27.4% in the last 12 months) and strong operating margins (37%) justify the investment, although high valuation ratios (P/E 120.8, P/S 17.8) compared to the S&P 500 (P/E 24.4, P/S 3.1) indicate significant risk.

cnbc.com

🌐 85% Global Worthiness

Feb 6, 22:09

Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher

Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.

Eli Lilly Q4 Earnings Beat Expectations, Sending Shares Higher

Eli Lilly's Q4 2024 revenue reached \$13.53 billion, a 45% year-over-year increase, exceeding adjusted EPS expectations; however, Mounjaro and Zepbound sales slightly missed forecasts, yet still contributed \$5.44 billion in revenue, boosting the stock to its highest level since October.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What were the key financial results of Eli Lilly's Q4 2024, and what is their immediate impact on the company's stock price?

Eli Lilly's Q4 2024 revenue surged 45% year-over-year to \$13.53 billion, exceeding adjusted EPS expectations at \$5.32 compared to the \$4.95 consensus. While Mounjaro and Zepbound sales slightly missed expectations at \$5.44 billion, the overall results boosted Lilly's stock to its highest point since October.

cnbc.com

🌐 75% Global Worthiness

Feb 5, 16:15

Stock Splits Surge: BofA Predicts Market-Beating Returns

Bank of America predicts a surge in stock splits, exceeding a decade-long trend, with companies like Netflix, Meta Platforms, and Eli Lilly as prime candidates; this could significantly boost returns for investors, exceeding average market performance.

Stock Splits Surge: BofA Predicts Market-Beating Returns

Bank of America predicts a surge in stock splits, exceeding a decade-long trend, with companies like Netflix, Meta Platforms, and Eli Lilly as prime candidates; this could significantly boost returns for investors, exceeding average market performance.

Progress

48% Bias Score

ShareSaveArticle

Reduced Inequality

12345678

Previous 1 of 8 Next

How might the trend of stock splits affect future investment strategies and the overall market dynamics in the coming years?

Companies like Netflix, Meta Platforms, and Eli Lilly are identified as potential candidates due to high share prices and strong recent performance. The increased accessibility of these stocks through splits could further boost investor interest and potentially drive market growth. The success of these splits may influence future corporate strategies.

cnbc.com

🌐 85% Global Worthiness

Jan 14, 22:08

Eli Lilly Stock Tumbles Despite Positive 2025 Outlook

Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...

Eli Lilly Stock Tumbles Despite Positive 2025 Outlook

Eli Lilly's stock fell over 7% on Tuesday after the company lowered its 2024 revenue outlook due to disappointing fourth-quarter sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound, which missed estimates by a combined $500 million, despite resolving supply chain issues and main...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What caused Eli Lilly's stock to plummet on Tuesday, and what are the immediate consequences of this decline?

Eli Lilly's stock dropped over 7% on Tuesday due to lowered 2024 revenue projections, primarily caused by underperforming sales of its GLP-1 weight-loss and diabetes drugs, Mounjaro and Zepbound. The shortfall, approximately $400 million below expectations, resulted in a revised revenue outlook of around $13.5 billion for the fourth quarter, missing Wall Street estimates by $400 million.

cnbc.com

🌐 85% Global Worthiness

Dec 23, 22:08

Eli Lilly Stock Soars on Obesity Drug Success

Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...

Eli Lilly Stock Soars on Obesity Drug Success

Eli Lilly's stock has risen 33.7% this year due to the success of its obesity drug Mounjaro, projected to generate \$5.1 billion in sales, exceeding initial forecasts by \$3.2 billion; the company is investing in manufacturing to meet demand and is awaiting FDA approval for expanded uses of its drug...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How is Eli Lilly addressing current supply chain challenges, and what are the long-term strategic implications of these actions?

The company's strategic investments in manufacturing capacity, coupled with efforts to alleviate drug shortages, underscore long-term confidence in the GLP-1 market. This proactive approach strengthens Eli Lilly's competitive position and positions it for sustained growth.

Showing 13 to 24 of 27 results